✦ LIBER ✦

Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

✍ Scribed by Michael Fiegl; Brigitte Mlineritsch; Michael Hubalek; Rupert Bartsch; Ursula Pluschnig; Günther G Steger

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Study of Bortezomib and Pegylat

✍ William J. Irvin Jr.; Robert Z. Orlowski; Wing-Keung Chiu; Lisa A. Carey; France 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 766 KB

Pegylated liposomal doxorubicin and gemc

✍ Adamo, V; Lorusso, V; Rossello, R; Adamo, B; Ferraro, G; Lorusso, D; Condemi, G; 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 126 KB

Non-pegylated liposomal doxorubicin comb

✍ S. Del Barco; R. Colomer; L. Calvo; I. Tusquets; E. Adrover; P. Sánchez; J. Rifà 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 220 KB

Impact of geriatric risk factors on pegy

✍ Falandry, C.; Brain, E.; Bonnefoy, M.; Mefti, F.; Jovenin, N.; Rigal, O.; Guille 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 438 KB

Reduced cardiotoxicity and comparable ef

✍ O'Brien, M. E. R. 📂 Article 📅 2004 🏛 Oxford University Press 🌐 English ⚖ 949 KB

Single agent carboplatin versus carbopla

✍ Maurie Markman; James Moon; Sharon Wilczynski; Ana Maria Lopez; Kendrith M. Rowl 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 218 KB